Decreased serum neurotrophin 3 in chronically medicated schizophrenic males

Neuroscience Letters

Volumn 440, Issue 3, 2008, Pages 197-201

  Vargas, Haroldo Evangelista ^a   Gama, Clarissa Severino ^a,b,c   Andreazza, Ana Cristina ^a,b   Medeiros, Dalton ^b   Stertz, Laura ^b   Fries, Gabriel ^b   Palha, Joana ^d   Cereser, Keila Maria ^a,b   Berk, Michael ^c,e,f   Kapczinski, Flavio ^a,b   Belmonte de Abreu, Paulo Silva ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF MINHO   (Portugal)

^e ORYGEN RESEARCH CENTRE   (Australia)

^f FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Antipsychotics; BDNF; Neurotrophins; NT3; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROTROPHIN 3; RISPERIDONE;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE; VEIN PUNCTURE;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALOPERIDOL; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROTROPHIN 3; PHLEBOTOMY; RISPERIDONE; SCHIZOPHRENIA;

EID: 45849105167     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.04.027     Document Type: Article

References (52)

1. Agerman K., and Ernfors P. Differential influence of BDNF and NT3 on the expression of calcium binding proteins and neuropeptide Y in vivo. Neuroreport 14 (2003) 2183-2187
2. Bersani G., Iannitelli A., Fiore M., Angelucci F., and Aloe L. Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders. Med. Hypotheses 55 (2000) 199-207
3. Craddock M., Asherson P., Owen M.J., Williams J., McGuffin P., and Farmer A.E. Concurrent validity of the OPCRIT diagnostic system-comparison of OPCRIT diagnoses with consensus best-estimate lifetime diagnoses. Br. J. Psychiatry 169 1 (1996) 58-63
4. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., Santin A., and Kapczinski F. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 398 3 (2006) 215-219
5. Dawson E., Powell J.F., Sham P.C., Nothen M., Crocq M.A., Propping P., Korner J., Rietschel M., Os J.V., and Wright P. An association study of a neurotrophin-3 (NT-3) gene polymorphism with schizophrenia. Acta Psychiatr. Scand. 92 (1995) 425-428
6. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., and Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 52 (2001) 79-86
7. Ernfors P., Ibanez C.F., Ebendal T., Olson L., and Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 5454-5458
8. Farinas I., Jones K.R., Backus C., Wang X.Y., and Reichardt L.F. Severe sensory and sympathetic deficits in mice lacking neurotrophin-3. Nature 369 (1994) 658-661
9. Felderhoff-Mueser U., Sifringer M., Pesditschek S., Kuckuck H., Moysich A., Bittigau P., and Ikonomidou C. Pathways leading to apoptopic neurodegenration folowing trauma to the developing rat brain. Neurobiol. Dis. 11 (2002) 231-245
10. Friedman W.J., Ibanez C.F., Hallbook F., Persson H., Cain L.D., Dreyfus C.F., and Black I.B. Differential actions of neurotrophins in the locus coeruleus and basal forebrain. Exp. Neurol. 119 (1993) 72-78
11. Gall C.M., Gold S.J., Isackson P.J., and Seroogy K.B. Brain derived neurotrophic factor and neurotrophin-3 mRNAs are expressed in ventral midbrain regions containing dopaminergic neurons. Mol. Cell. Neurosci. 3 (1992) 56-63
12. Gama C.S., Andreazza A.C., Kunz M., Berk M., Silva Belmonte-de-Abreu P., and Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci. Lett. 420 1 (2007) 45-48
13. Gama C.S., Salvador M., Andreazza A.C., Kapczinski F., and Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Progr. Neuropsychopharmacol. Biol. Psychiatry 30 3 (2006) 512-515
14. Gama C.S., Salvador M., Andreazza A.C., Lobato M.I., Berk M., Kapczinski F., and Silva Belmonte-de-Abreu P. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci. Lett. 433 (2008) 270-273
15. Giehl K.M., R̈ohrig S., Bonatz H., Gutjahr M., Leiner B., Bartke I., Yan Q., Reichardt L.F., Backus C., Welcher A.A., Dethleffsen K., Mestres P., and Meyer M. Endogenous brain-derived neurotrophic factor and neurotrophin-3 antagonistically regulate survival of axotomized corticospinal neurons in vivo. J. Neurosci. 21 (2001) 3492-3502
16. Gilmore J.H., Jarskog L.F., Lindgren J.C., McEvoy J.P., and Xiao H. Neurotrophin-3 levels in the cerebrospinal fluid of patients with schizophrenia or medical illness. Psychiatry Res. 73 (1997) 109-113
17. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., Monteggia L.M., Pierri J.N., Sun Z., Sampson A.R., and Lewis D.A. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J. Neurosci. 25 2 (2005) 372-383
18. Hattori M., and Nanko S. Association of neurotrophin-3 gene variant with severe forms of schizophrenia. Biochem. Biophys. Res. Commun. 209 (1995) 513-518
19. Hohn A., Leibrock J., Bailey K., and Barde Y.A. Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family. Nature 344 (1990) 339-341
20. Huang T.L., and Lee C.T. Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J. Psychiatr. Res. 40 (2006) 664-668
21. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., Kauer-Sant'anna M., Grassi-Oliveira R., and Post R.M. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 32 4 (2008) 675-692
22. Kato T. Bridging pharmacology and neurodevelopment in schizophrenia. Int. J. Neuropsychopharmacol. 10 6 (2007) 713-716
23. Lang U.E., Jockers-Scherubl M.C., and Hellweg R. State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. J. Neural Transm. 111 (2004) 387-411
24. Lewin G.R., and Barde Y.A. Physiology of the neurotrophins. Annu. Rev. Neurosci. 19 (1996) 289-317
25. Lieberman J.A. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J. Clin. Psychiatry 60 Suppl. 12 (1999) 9-12
26. Linden A.M., Vaisanen J., Lakso M., Nawa H., Wong G., and Castren E. Expression of neurotrophins in rat brain after administration of antipsychotic and psychotropic agents. J. Mol. Neurosci. 14 (2000) 27-37
27. Maisonpierre P.C., Belluscio L., Friedman B., Alderson R.F., Wiegand S.J., Furth M.E., Lindsay R.M., and Yancopoulos G.D. NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron 5 (1990) 501-509
28. Maisonpierre P.C., Belluscio L., Squinto S., Ip N.Y., Furth M.E., Lindsay R.M., and Yancopoulos G.D. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science 247 (1990) 1446-1451
29. Maisonpierre P.C., Le Beau M.M., Espinosa III R., Ip N.Y., Belluscio L., de la Monte S.M., Squinto S., Furth M.E., and Yancopoulos G.D. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 10 (1991) 558-568
30. Minichiello L., and Klein R. TrkB and TrkC neurotrophin receptors cooperate in promoting survival of hippocampal and cerebellar granule neurons. Genes Dev. 10 (1996) 2849-2858
31. Ng F., Berk M., Dean O., and Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. January (2008) 1-26 (Epub ahead of print)
32. Noga O., Englmann C., Hanf G., Grützkau A., Seybold J., and Kunkel G. The production, storage and release of neurotrophins nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 by human peripheral eosinophils in allergics and non-allergics. Clin. Exp. Allergy 33 (2003) 649-654
33. Palomino A., Vallejo-Illarramendi A., Gonzalez-Pinto A., Aldama A., Gonzalez-Gomez C., Mosquera F., Gonzalez-Garcia G., and Matute C. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr. Res. 86 1-3 (2006) 321-322
34. Pan W., Banks W.A., and Kastin A.J. Permeability of the blood-brain barrier to neurotrophins. Brain Res. 788 (1998) 87-94
35. Pi{dotless}ri{dotless}ldara S., Gonul A.S., Tanelib F., and Akdeniza F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Progr. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 709-713
36. Poduslo J.F., and Curran G.L. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Mol. Brain Res. 36 (1996) 280-286
37. Qian L., Zhao J., Shi Y., Zhao X., Feng G., Xu F., Zhu S., and He L. Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis. Biochem. Biophys. Res. Commun. 353 3 (2007) 738-743
38. Romano F., and Elkis H. Tradução e Adaptação de um Instrumento de Avaliação Psicopatológica das Psicoses: a Escala Breve de Avaliação Psiquiátrica. Versão Ancorada (BPRS-A). Jornal Brasileiro de Psiquiatria 45 (1996) 43-49
39. Rost B., Hanf G., Ohnemus U., Otto-Knapp R., Groneberg D.A., Kunkel G., and Noga O. Monocytes of allergics and non-allergics produce, store and release the neurotrophins NGF, BDNF and NT-3. Regul. Pept. 124 (2005) 19-25
40. Schutte A., Yan Q., Mestres P., and Giehl K.M. The endogenous survival promotion of axotomized rat corticospinal neurons by brain-derived neurotrophic factor is mediated via paracrine, rather than autocrine mechanisms. Neurosci. Lett. 290 (2000) 185-188
41. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., and Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci. Lett. 351 (2003) 111-114
42. Shirayama Y., Chen A.C., Nakagawa S., Russel D.S., and Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22 (2002) 3251-3261
43. Smith M.A., Makino S., Altemus M., Michelson D., Hong S.K., Kvetnansky R., and Post R.M. Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in the locus coeruleus. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 8788-8792
44. Strakowski S.M., DelBello M.P., Zimmerman M.E., Getz G.E., Mills N.P., Ret J., Shear P., and Adler C.M. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am. J. Psychiatry 159 11 (2002) 1841-1847
45. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., Koizumi S., Wakabayashi K., Takahashi H., Someya T., and Nawa H. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol. Psychiatry 5 3 (2000) 293-300
46. Tan Y.L., Zhoua D.F., Caob L.Y., Zoub Y.Z., and Zhang X.Y. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci. Lett. 382 (2005) 27-32
47. Toyookaa K., Asamac K., Watanabea Y., Muratakeb T., Takahashib M., Someyab T., and Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 110 (2002) 249-257
48. Velakoulis D., Wood S.J., Wong M.T., McGorry P.D., Yung A., Phillips L., Smith D., Brewer W., Proffitt T., Desmond P., and Pantelis C. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch. Gen. Psychiatry 63 2 (2006) 139-149
49. Walz J.C., Andreazza A.C., Frey B.N., Cacilhas A.A., Cereser K.M.M., Cunha A.B.M., Weyne F., Stertz L., Santin A., Gonçalves C.A., and Kapczinski F. Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neurosci. Lett. 415 (2007) 87-89
50. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., Hyde T.M., Herman M.M., Weinberger D.R., and Kleinman J.E. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 10 7 (2005) 637-650
51. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Haile C.N., Kosten T.A., and Kosten T.R. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J. Psychiatr. Res. 41 (2007) 997-1004
52. Zhang X.Y., Zhou D.F., Wu G.Y., Cao L.Y., Tan Y.L., Haile C.N., Li J., Lu L., Kosten T.A., and Kosten T.R. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology November (2007) 10.1038/sj.npp.1301619